Drug
Ro7795081
Ro7795081: highest development phase Phase 1, developed by Roche. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| RO7795081 NCT07741604 | Phase 1 | Renal Impairment |
| RO7795081 NCT07499050 | Phase 1 | Overweight or Obesity |
Latest
No recent events.
Follow Ro7795081 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.